Angiotensin Therapeutics Inc.
Angiotensin Therapeutics Inc. is a privately held biopharmaceutical company focused on developing breakthrough therapies for COVID 19 and other potential Coronavirus outbreaks as well as for treatment of Kidney Disease.
Our main biologics are variants of a natural enzyme called Angiotensin Converting Enzyme 2 (ACE2). One of our ACE2 variants has been modified to increase the duration of action from hours to days which makes it much more suitable therapeutically. The potential therapeutic applications for this and other variants are COVID-19 as ongoing preclinical studies show promise. As ACE2 is the receptor of coronavirus entry into cells, our approach is based on intercepting the virus from reaching the ACE2 receptor in the cell membranes.
Other potential applications, among others, include acute kidney injury (AKI), which is a common complication of cardiac surgery and of decompensated heart failure and chronic kidney disease (CKD). Kidney Disease is a devastating illness costing over $100 billion in annual care.